Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsiesReportar como inadecuado

Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Molecular Cancer

, 5:24

First Online: 19 June 2006Received: 04 April 2006Accepted: 19 June 2006


BackgroundRecent studies indicate that microRNAs miRNAs are mechanistically involved in the development of various human malignancies, suggesting that they represent a promising new class of cancer biomarkers. However, previously reported methods for measuring miRNA expression consume large amounts of tissue, prohibiting high-throughput miRNA profiling from typically small clinical samples such as excision or core needle biopsies of breast or prostate cancer. Here we describe a novel combination of linear amplification and labeling of miRNA for highly sensitive expression microarray profiling requiring only picogram quantities of purified microRNA.

ResultsComparison of microarray and qRT-PCR measured miRNA levels from two different prostate cancer cell lines showed concordance between the two platforms Pearson correlation R = 0.81; and extension of the amplification, labeling and microarray platform was successfully demonstrated using clinical core and excision biopsy samples from breast and prostate cancer patients. Unsupervised clustering analysis of the prostate biopsy microarrays separated advanced and metastatic prostate cancers from pooled normal prostatic samples and from a non-malignant precursor lesion. Unsupervised clustering of the breast cancer microarrays significantly distinguished ErbB2-positive-ER-negative, ErbB2-positive-ER-positive, and ErbB2-negative-ER-positive breast cancer phenotypes Fisher exact test, p = 0.03; as well, supervised analysis of these microarray profiles identified distinct miRNA subsets distinguishing ErbB2-positive from ErbB2-negative and ER-positive from ER-negative breast cancers, independent of other clinically important parameters patient age; tumor size, node status and proliferation index.

ConclusionIn sum, these findings demonstrate that optimized high-throughput microRNA expression profiling offers novel biomarker identification from typically small clinical samples such as breast and prostate cancer biopsies.

Electronic supplementary materialThe online version of this article doi:10.1186-1476-4598-5-24 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Michael D Mattie - Christopher C Benz - Jessica Bowers - Kelly Sensinger - Linda Wong - Gary K Scott - Vita Fedele - Dav

Fuente: https://link.springer.com/

Documentos relacionados